SCHEMBL4615333

SCHEMBL4615333

Cc1ccc(C(C(N)=O)C(N)=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.53
LMNA P02545 2/20 0.50
ALDH1A1 P00352 5/20 0.44
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
ACHE P22303 2/20 0.44
CYP2C19 P33261 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
KIF11 P52732 1/20 0.42
CHRNA7 P36544 1/20 0.41
STAT3 P40763 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
SCN5A Q14524 1/20 0.40
SCN2A Q99250 1/20 0.40
EPHX1 P07099 1/20 0.39
PKM P14618 1/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.39
ATM Q13315 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11212242 0.89 LMNA (0.50) ALOX5LMNAALDH1A1CES2CES1
SCHEMBL3054675 0.81 EPHX1 (0.60) ALOX5LMNAALDH1A1CES2CES1
SCHEMBL987111 0.81 ALOX5 (0.50) ALOX5LMNAALDH1A1CES2CES1
SCHEMBL16750533 0.81 EPHX1 (0.60) ALOX5LMNAALDH1A1CES2CES1
SCHEMBL16750532 0.81 ALOX5 (0.50) ALOX5LMNAALDH1A1CES2CES1
SCHEMBL1667154 0.80 STAT3 (0.44) ALOX5LMNAALDH1A1CES2CES1
SCHEMBL1821047 0.80 SRC (0.61) ALOX5LMNAALDH1A1CES2CES1
SCHEMBL7282243 0.79 ALOX5 (0.48) ALOX5LMNAALDH1A1CES2CES1
SCHEMBL8763327 0.79 ALOX5 (0.48) ALOX5LMNAALDH1A1CES2CES1
SCHEMBL21269213 0.78 SRC (0.58) ALOX5LMNAALDH1A1CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3118613-A1 ELECTRIC COMPONENT WITH ORGANIC PART ACREO SWEDISH ICT AB (SE) 2017-01-18 EP disclosed
EP-2779261-B1 Ferroelectric field-effect transistor ACREO SWEDISH ICT AB (SE) 2016-11-30 EP disclosed
US-9318596-B2 Ferroelectric field-effect transistor ACREO SWEDISH ICT AB (SE) 2016-04-19 US disclosed
US-20140264515-A1 FERROELECTRIC FIELD-EFFECT TRANSISTOR ACREO SWEDISH ICT AB (SE) 2014-09-18 US disclosed
EP-2779261-A1 Ferroelectric field-effect transistor Acreo Swedish ICT AB (SE) 2014-09-17 EP disclosed
US-8501046-B2 Use of rylene derivatives as photosensitizers in solar cells BASF SE (DE) 2013-08-06 US disclosed
US-20120283432-A1 USE OF RYLENE DERIVATIVES AS PHOTOSENSITIZERS IN SOLAR CELLS MAX-PLANCK-GESEL. ZUR FOERDERUNG DER WISSEN. E.V. (DE) 2012-11-08 US disclosed
US-8231809-B2 Solid p-semiconductors may also be used in the inventive dye-sensitized solar cells without increasing the cell resistance, since the rylene derivatives absorb strongly and therefore require only thin n-semiconductor layers BASF AKTIENGESELLSCHAFT (DE) 2012-07-31 US disclosed
US-20080269482-A1 Use of Rylene Derivatives as Photosensitizers in Solar Cells BASF SE (DE) 2008-10-30 US disclosed
US-5340861-A Containing organic titanium or zirconium compound INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 1994-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283432-A1 USE OF RYLENE DERIVATIVES AS PHOTOSENSITIZERS IN SOLAR CELLS NR2E3, NR2E1, NR1D2 ALOX5 391/4885LMNA 2818/4885ALDH1A1 4248/4885
US-20080269482-A1 Use of Rylene Derivatives as Photosensitizers in Solar Cells NR2E3, NR2E1, NR1D2 ALOX5 450/4885LMNA 2900/4885ALDH1A1 4269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.